Treatment in esophagogastric junction cancer: Past, present and future.
Sign Up to like & getrecommendations! Published in 2019 at "Cirugia espanola"
DOI: 10.1016/j.ciresp.2019.03.016
Abstract: Adenocarcinomas of the gastroesophageal junction represent 27% of all gastric tumors. n recent years, it has been classified as an entity of its own, with specific treatments that are sometimes differentiated from gastric treatments. Treatment… read more here.
Keywords: treatment esophagogastric; junction cancer; treatment; cancer past ... See more keywords
Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Management and Research"
DOI: 10.2147/cmar.s341468
Abstract: Abstract Esophagogastric cancers are aggressive malignancies, with poor prognosis despite current standard-of-care therapies. PD-1 inhibitors are a newer class of antitumor agents with the potential to improve outcomes among appropriately selected patients. This review provides… read more here.
Keywords: treatment esophagogastric; role; role inhibitors; inhibitors treatment ... See more keywords